FierceBiotech 2026-01-02 NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership
FierceBiotech 2026-01-02 Sanofi, Corcept surprised by FDA rejections for MS, Cushing's syndrome drugs
FierceBiotech 2026-01-02 Neuralink to kick-start 'high-volume production' of brain-computer interface devices, Elon Musk says
FierceBiotech 2026-01-02 Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease
FierceBiotech 2026-01-02 AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals
FierceBiotech 2026-01-02 Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout
FierceBiotech 2026-01-02 Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials
FierceBiotech 2025-12-31 Quanterix's blood test for Alzheimer's disease uncovers potentially treatable population in decades-long study
FierceBiotech 2025-12-30 Breast cancer tops list of most-studied diseases for 5th year in a row: report
FierceBiotech 2025-12-23 Edwards nets FDA approval for Sapien M3 transcatheter mitral valve replacement
FierceBiotech 2025-12-23 Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spree
FierceBiotech 2025-12-23 Despite geopolitical pressures, China biotech deals remain at pace as collective value soars: Evaluate
FierceBiotech 2025-12-23 Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data
FierceBiotech 2025-12-23 Miracle babies, antibiotic improv and T-cell tamers: Fierce's favorite research stories of 2025
FierceBiotech 2025-12-22 BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement